Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| MAIA Biotechnology Inc. | Ateganosine (THIO-102) | Colorectal cancer, Hepatocellular carcinoma (HCC), and Small cell lung cancer (SCLC) | Phase 2 | Trial Planned | Oral | Oncology |
| MAIA Biotechnology Inc. | Ateganosine (THIO-101) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Oral | Oncology |
| Mallinckrodt plc | Terlipressin | Hepatorenal syndrome (HRS) Type 1 | NDA Filing | Intravenous | N/A | |
| MannKind Corporation | FUROSCIX ReadyFlow Autoinjector (SCP-111) | Edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD) | PDUFA | Ongoing | Subcutaneous | Cardiology |
| MannKind Corporation | Afrezza (Technosphere Insulin) - (INHALE-1) | Pediatric type 1/2 diabetes | PDUFA | Ongoing | Inhalation | Endocrinology |
| MannKind Corporation | Afrezza Combined With Insulin Degludec - (INHALE-3) | Type 1 Diabetes | Phase 3 | Data Released | Inhalation | Endocrinology |
| MannKind Corporation | Inhaled Clofazimine (MNKD-101) - (ICoN-1) | Nontuberculous mycobacterial (NTM) lung disease | Phase 3 | Trial Discontinued | Inhalation | Respiratory |
| MannKind Corporation | Nintedanib Dpi (Mnkd-201) | Pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) | Phase 2 | Trial Planned | Inhalation | Respiratory |
